Detrimental effects of antiapoptotic treatments in spinal cord injury

Diana M. Cittelly, Olivera Nesic, Kathia Johnson, Claire Hulsebosch, J. Regino Perez-Polo

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Long-term functional impairments due to spinal cord injury (SCI) in the rat result from secondary apoptotic death regulated, in part, by SCI-induced decreases in protein levels of the antiapoptotic protein Bcl-xL. We have shown that exogenous administration of Bcl-xL spares neurons 24 h after SCI. However, long-term effects of chronic application of Bcl-xL have not been characterized. To counteract SCI-induced decreases in Bcl-xL and resulting apoptosis, we used the TAT protein transduction domain fused to the Bcl-xL protein (Tat-Bcl-xL), or its antiapoptotic domain BH4 (Tat-BH4). We used intrathecal delivery of Tat-Bcl-xL, or Tat-BH4, into injured spinal cords for 24 h or 7 days, and apoptosis, neuronal death and locomotor recovery were assessed up to 2 months after injury. Both, Tat-Bcl-xL and Tat-BH4, significantly decreased SCI-induced apoptosis in thoracic segments containing the site of injury (T10) at 24 h or 7 days after SCI. However, the 7-day delivery of Tat-Bcl-xL, or Tat-BH4, also induced a significant impairment of locomotor recovery that lasted beyond the drug delivery time. We found that the 7-day administration of Tat-Bcl-xL, or Tat-BH4, significantly increased non-apoptotic neuronal loss and robustly augmented microglia/macrophage activation. These results indicate that the antiapoptotic treatment targeting Bcl-xL shifts neuronal apoptosis to necrosis, increases the inflammatory response and impairs locomotor recovery. Our results suggest that a combinatorial treatment consisting of antiapoptotic and anti-inflammatory agents may be necessary to achieve tissue preservation and significant improvement in functional recovery after SCI.

    Original languageEnglish (US)
    Pages (from-to)295-307
    Number of pages13
    JournalExperimental Neurology
    Volume210
    Issue number2
    DOIs
    StatePublished - Apr 2008

    Fingerprint

    Spinal Cord Injuries
    tat Gene Products
    Apoptosis
    Tissue Preservation
    Proteins
    Macrophage Activation
    Wounds and Injuries
    Microglia
    Spinal Cord
    Anti-Inflammatory Agents
    Necrosis
    Thorax
    Neurons
    Therapeutics
    Pharmaceutical Preparations

    Keywords

    • Apoptosis
    • Cell death
    • Inflammation
    • Microglia
    • Spinal cord injury
    • Tat-Bcl-x
    • Tat-BH4

    ASJC Scopus subject areas

    • Neurology
    • Neuroscience(all)

    Cite this

    Cittelly, D. M., Nesic, O., Johnson, K., Hulsebosch, C., & Perez-Polo, J. R. (2008). Detrimental effects of antiapoptotic treatments in spinal cord injury. Experimental Neurology, 210(2), 295-307. https://doi.org/10.1016/j.expneurol.2007.03.001

    Detrimental effects of antiapoptotic treatments in spinal cord injury. / Cittelly, Diana M.; Nesic, Olivera; Johnson, Kathia; Hulsebosch, Claire; Perez-Polo, J. Regino.

    In: Experimental Neurology, Vol. 210, No. 2, 04.2008, p. 295-307.

    Research output: Contribution to journalArticle

    Cittelly, DM, Nesic, O, Johnson, K, Hulsebosch, C & Perez-Polo, JR 2008, 'Detrimental effects of antiapoptotic treatments in spinal cord injury', Experimental Neurology, vol. 210, no. 2, pp. 295-307. https://doi.org/10.1016/j.expneurol.2007.03.001
    Cittelly, Diana M. ; Nesic, Olivera ; Johnson, Kathia ; Hulsebosch, Claire ; Perez-Polo, J. Regino. / Detrimental effects of antiapoptotic treatments in spinal cord injury. In: Experimental Neurology. 2008 ; Vol. 210, No. 2. pp. 295-307.
    @article{4e35c8c4fad64f5e9054753a5124c9f0,
    title = "Detrimental effects of antiapoptotic treatments in spinal cord injury",
    abstract = "Long-term functional impairments due to spinal cord injury (SCI) in the rat result from secondary apoptotic death regulated, in part, by SCI-induced decreases in protein levels of the antiapoptotic protein Bcl-xL. We have shown that exogenous administration of Bcl-xL spares neurons 24 h after SCI. However, long-term effects of chronic application of Bcl-xL have not been characterized. To counteract SCI-induced decreases in Bcl-xL and resulting apoptosis, we used the TAT protein transduction domain fused to the Bcl-xL protein (Tat-Bcl-xL), or its antiapoptotic domain BH4 (Tat-BH4). We used intrathecal delivery of Tat-Bcl-xL, or Tat-BH4, into injured spinal cords for 24 h or 7 days, and apoptosis, neuronal death and locomotor recovery were assessed up to 2 months after injury. Both, Tat-Bcl-xL and Tat-BH4, significantly decreased SCI-induced apoptosis in thoracic segments containing the site of injury (T10) at 24 h or 7 days after SCI. However, the 7-day delivery of Tat-Bcl-xL, or Tat-BH4, also induced a significant impairment of locomotor recovery that lasted beyond the drug delivery time. We found that the 7-day administration of Tat-Bcl-xL, or Tat-BH4, significantly increased non-apoptotic neuronal loss and robustly augmented microglia/macrophage activation. These results indicate that the antiapoptotic treatment targeting Bcl-xL shifts neuronal apoptosis to necrosis, increases the inflammatory response and impairs locomotor recovery. Our results suggest that a combinatorial treatment consisting of antiapoptotic and anti-inflammatory agents may be necessary to achieve tissue preservation and significant improvement in functional recovery after SCI.",
    keywords = "Apoptosis, Cell death, Inflammation, Microglia, Spinal cord injury, Tat-Bcl-x, Tat-BH4",
    author = "Cittelly, {Diana M.} and Olivera Nesic and Kathia Johnson and Claire Hulsebosch and Perez-Polo, {J. Regino}",
    year = "2008",
    month = "4",
    doi = "10.1016/j.expneurol.2007.03.001",
    language = "English (US)",
    volume = "210",
    pages = "295--307",
    journal = "Experimental Neurology",
    issn = "0014-4886",
    publisher = "Academic Press Inc.",
    number = "2",

    }

    TY - JOUR

    T1 - Detrimental effects of antiapoptotic treatments in spinal cord injury

    AU - Cittelly, Diana M.

    AU - Nesic, Olivera

    AU - Johnson, Kathia

    AU - Hulsebosch, Claire

    AU - Perez-Polo, J. Regino

    PY - 2008/4

    Y1 - 2008/4

    N2 - Long-term functional impairments due to spinal cord injury (SCI) in the rat result from secondary apoptotic death regulated, in part, by SCI-induced decreases in protein levels of the antiapoptotic protein Bcl-xL. We have shown that exogenous administration of Bcl-xL spares neurons 24 h after SCI. However, long-term effects of chronic application of Bcl-xL have not been characterized. To counteract SCI-induced decreases in Bcl-xL and resulting apoptosis, we used the TAT protein transduction domain fused to the Bcl-xL protein (Tat-Bcl-xL), or its antiapoptotic domain BH4 (Tat-BH4). We used intrathecal delivery of Tat-Bcl-xL, or Tat-BH4, into injured spinal cords for 24 h or 7 days, and apoptosis, neuronal death and locomotor recovery were assessed up to 2 months after injury. Both, Tat-Bcl-xL and Tat-BH4, significantly decreased SCI-induced apoptosis in thoracic segments containing the site of injury (T10) at 24 h or 7 days after SCI. However, the 7-day delivery of Tat-Bcl-xL, or Tat-BH4, also induced a significant impairment of locomotor recovery that lasted beyond the drug delivery time. We found that the 7-day administration of Tat-Bcl-xL, or Tat-BH4, significantly increased non-apoptotic neuronal loss and robustly augmented microglia/macrophage activation. These results indicate that the antiapoptotic treatment targeting Bcl-xL shifts neuronal apoptosis to necrosis, increases the inflammatory response and impairs locomotor recovery. Our results suggest that a combinatorial treatment consisting of antiapoptotic and anti-inflammatory agents may be necessary to achieve tissue preservation and significant improvement in functional recovery after SCI.

    AB - Long-term functional impairments due to spinal cord injury (SCI) in the rat result from secondary apoptotic death regulated, in part, by SCI-induced decreases in protein levels of the antiapoptotic protein Bcl-xL. We have shown that exogenous administration of Bcl-xL spares neurons 24 h after SCI. However, long-term effects of chronic application of Bcl-xL have not been characterized. To counteract SCI-induced decreases in Bcl-xL and resulting apoptosis, we used the TAT protein transduction domain fused to the Bcl-xL protein (Tat-Bcl-xL), or its antiapoptotic domain BH4 (Tat-BH4). We used intrathecal delivery of Tat-Bcl-xL, or Tat-BH4, into injured spinal cords for 24 h or 7 days, and apoptosis, neuronal death and locomotor recovery were assessed up to 2 months after injury. Both, Tat-Bcl-xL and Tat-BH4, significantly decreased SCI-induced apoptosis in thoracic segments containing the site of injury (T10) at 24 h or 7 days after SCI. However, the 7-day delivery of Tat-Bcl-xL, or Tat-BH4, also induced a significant impairment of locomotor recovery that lasted beyond the drug delivery time. We found that the 7-day administration of Tat-Bcl-xL, or Tat-BH4, significantly increased non-apoptotic neuronal loss and robustly augmented microglia/macrophage activation. These results indicate that the antiapoptotic treatment targeting Bcl-xL shifts neuronal apoptosis to necrosis, increases the inflammatory response and impairs locomotor recovery. Our results suggest that a combinatorial treatment consisting of antiapoptotic and anti-inflammatory agents may be necessary to achieve tissue preservation and significant improvement in functional recovery after SCI.

    KW - Apoptosis

    KW - Cell death

    KW - Inflammation

    KW - Microglia

    KW - Spinal cord injury

    KW - Tat-Bcl-x

    KW - Tat-BH4

    UR - http://www.scopus.com/inward/record.url?scp=41149152155&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=41149152155&partnerID=8YFLogxK

    U2 - 10.1016/j.expneurol.2007.03.001

    DO - 10.1016/j.expneurol.2007.03.001

    M3 - Article

    VL - 210

    SP - 295

    EP - 307

    JO - Experimental Neurology

    JF - Experimental Neurology

    SN - 0014-4886

    IS - 2

    ER -